PRKAG2 and prostate carcinoma: In addition, other LKB1 pathway components, such as CAB39L (Fig. 2i; Supplementary information, Fig. S2m), an activator of LKB1,17 and PRKAG1 (Fig. 2j; Supplementary information, Fig. S2n) and PRKAG2 (Fig. 2k; Supplementary information, Fig. S2o), two downstream effectors, were significantly downregulated in AR-low prostate cancers.